Teicoplanin population pharmacokinetic analysis in hospitalized patients

被引:36
作者
Soy, Dolors [1 ]
Lopez, Ester [1 ]
Ribas, Josep [1 ]
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Serv Pharm, E-08036 Barcelona, Spain
关键词
population pharmacokinetics; teicoplanin; therapeutic drug monitoring;
D O I
10.1097/01.ftd.0000249942.14145.ff
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The goal of this study was to build a population pharmacokinetic (PK) model to characterize the population PK parameters in our hospitalized patients. Teicoplanin serum concentrations from clinical routine were used. Antibiotic dose history and blood collection times were recorded and analyzed with NONMEM-V Demographic and biologic data creatinine clearance (CLcr) weight (WT), and albumin (Alb) were tested for inclusion as covariates in the basic model. Intraindividual and residual variability were modeled. One hundred seven sparse samples (mainly trough levels), from 79 patients, were included. A 2-compartment PK model characterized by clearance (CL), central compartment volume of distribution (V-c), intercompartment clearance, and steady-state volume of distribution (V-ss) with first-order elimination adequately described the data. CLcr and WT significantly influenced teicoplanin CL (CL = 0.57[0.15]* (1 + 0.0048[0.39]*(CLcr - averageCL(cr))*WT) L/h). V-ss was not affected by any covariate (V-ss = 50.2[0.13]L). A negative trend between Alb and individual Vss estimates was observed without statistical significance. In a new data set, bias and precision resulted in mean values of -3.24% and 9.42%, respectively. In conclusion, CLcr and WT are significant covariates on teicoplanin CL. Results from predictive accuracy and precision show the usefulness of this model for implementation in a therapeutic drug monitoring program in the near future.
引用
收藏
页码:737 / 743
页数:7
相关论文
共 36 条
[1]   COMPARATIVE EFFECT OF PROTEIN-BINDING ON THE KILLING ACTIVITIES OF TEICOPLANIN AND VANCOMYCIN [J].
BAILEY, EM ;
RYBAK, MJ ;
KAATZ, GW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1089-1092
[2]   Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors [J].
Barbot, A ;
Venisse, N ;
Rayeh, F ;
Bouquet, S ;
Debaene, B ;
Mimoz, O .
INTENSIVE CARE MEDICINE, 2003, 29 (09) :1528-1534
[3]  
Beal SL., 1989, NONMEM 7 4 USERS GUI
[4]   TEICOPLANIN - A REAPPRAISAL OF ITS ANTIMICROBIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
BROGDEN, RN ;
PETERS, DH .
DRUGS, 1994, 47 (05) :823-854
[5]   EFFECTS OF DOSAGE, PEAK AND TROUGH CONCENTRATIONS IN SERUM, PROTEIN-BINDING, AND BACTERICIDAL RATE ON EFFICACY OF TEICOPLANIN IN A RABBIT MODEL OF ENDOCARDITIS [J].
CHAMBERS, HF ;
KENNEDY, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (04) :510-514
[6]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[7]   Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid [J].
Craig, WA .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :479-+
[8]   Model appropriateness and population pharmacokinetic modeling [J].
Ette, EL ;
Williams, PJ ;
Kim, YH ;
Lane, JR ;
Liu, MJ ;
Capparelli, EV .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06) :610-623
[9]   CLINICAL-EVALUATION OF TEICOPLANIN FOR THERAPY OF SEVERE INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA [J].
GLUPCZYNSKI, Y ;
LAGAST, H ;
VANDERAUWERA, P ;
THYS, JP ;
CROKAERT, F ;
YOURASSOWSKY, E ;
MEUNIERCARPENTIER, F ;
KLASTERSKY, J ;
KAINS, JP ;
SERRUYSSCHOUTENS, E ;
LEGRAND, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (01) :52-57
[10]   Biosynthetic studies of the glycopeptide teicoplanin by 1H and 13C NMR [J].
Heydorn, A ;
Petersen, BO ;
Duus, JO ;
Bergmann, S ;
Suhr-Jessen, T ;
Nielsen, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (09) :6201-6206